BG63967B1 - Сулфонамидни инхибитори на матрични металопротеинази - Google Patents
Сулфонамидни инхибитори на матрични металопротеинази Download PDFInfo
- Publication number
- BG63967B1 BG63967B1 BG102448A BG10244898A BG63967B1 BG 63967 B1 BG63967 B1 BG 63967B1 BG 102448 A BG102448 A BG 102448A BG 10244898 A BG10244898 A BG 10244898A BG 63967 B1 BG63967 B1 BG 63967B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- benzenesulfonylamino
- acid
- phenylpiperidin
- compound
- phenyl
- Prior art date
Links
- 0 *C(*c(cc1)ccc1I)C(*)C(O)=O Chemical compound *C(*c(cc1)ccc1I)C(*)C(O)=O 0.000 description 10
- PYNVCLKSPOVPHB-UHFFFAOYSA-N C=[S](c(cc1)ccc1F)(Cl)(=O)=O Chemical compound C=[S](c(cc1)ccc1F)(Cl)(=O)=O PYNVCLKSPOVPHB-UHFFFAOYSA-N 0.000 description 1
- BFXHJFKKRGVUMU-UHFFFAOYSA-N O=S(c(cc1)ccc1F)(Cl)=O Chemical compound O=S(c(cc1)ccc1F)(Cl)=O BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US737295P | 1995-11-17 | 1995-11-17 | |
PCT/US1996/016761 WO1997019068A1 (en) | 1995-11-17 | 1996-10-18 | Sulfonamide inhibitors of matrix metalloproteinases |
Publications (2)
Publication Number | Publication Date |
---|---|
BG102448A BG102448A (en) | 1999-08-31 |
BG63967B1 true BG63967B1 (bg) | 2003-08-29 |
Family
ID=21725784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG102448A BG63967B1 (bg) | 1995-11-17 | 1998-05-13 | Сулфонамидни инхибитори на матрични металопротеинази |
Country Status (20)
Country | Link |
---|---|
US (3) | US5977141A (de) |
EP (1) | EP0874836B1 (de) |
JP (1) | JP2000514779A (de) |
AT (1) | ATE225779T1 (de) |
AU (1) | AU727569B2 (de) |
BG (1) | BG63967B1 (de) |
BR (1) | BR9611487A (de) |
CZ (1) | CZ291659B6 (de) |
DE (1) | DE69624262T2 (de) |
DK (1) | DK0874836T3 (de) |
ES (1) | ES2184893T3 (de) |
HU (1) | HUP9902083A3 (de) |
IL (1) | IL123901A (de) |
NO (1) | NO310231B1 (de) |
NZ (1) | NZ321293A (de) |
PL (1) | PL326700A1 (de) |
PT (1) | PT874836E (de) |
SK (1) | SK282833B6 (de) |
WO (1) | WO1997019068A1 (de) |
ZA (1) | ZA969584B (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
CN1542002A (zh) * | 1995-12-08 | 2004-11-03 | ������ҩ������˾ | 金属蛋白酶抑制剂,含有它们的药物组合物和其药物用途,其制备方法和中间体 |
US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
US6747027B1 (en) * | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
KR20000068415A (ko) | 1996-09-04 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법 |
BR9711988A (pt) * | 1996-09-04 | 1999-08-24 | Warner Lambert Co | Inibidores de metaloproteinase de matriz e seus empregos terap-uticos |
US6624177B1 (en) | 1996-09-04 | 2003-09-23 | Warner-Lambert Company | Matrix metalloproteinase inhibitors and their therapeutic uses |
US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US5929097A (en) * | 1996-10-16 | 1999-07-27 | American Cyanamid Company | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US5962481A (en) | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US5977408A (en) * | 1996-10-16 | 1999-11-02 | American Cyanamid Company | Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US6228869B1 (en) | 1996-10-16 | 2001-05-08 | American Cyanamid Company | Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
IL128545A0 (en) * | 1996-12-09 | 2000-01-31 | Warner Lambert Co | Method for treating and preventing heart failure and ventricular dilatation |
DE69727695T2 (de) | 1996-12-17 | 2005-02-10 | Warner-Lambert Co. Llc | Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung |
EP1366765A1 (de) * | 1996-12-17 | 2003-12-03 | Warner-Lambert Company Llc | VerWendung von Matrix-Metalloproteinase Inhibitoren zur Behandlung von neurologischen Erkrankungen und zur Förderung der Wundheilung |
US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
ES2241133T3 (es) * | 1997-04-28 | 2005-10-16 | Encysive Pharmaceuticals Inc. | Sulfamidas para el tratamiento de los trastornos inducidos por la endotelina. |
EP0877019B1 (de) * | 1997-05-09 | 2001-12-12 | Hoechst Aktiengesellschaft | Substituierte Diaminocarbonsäuren |
DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
HUP0101176A3 (en) | 1998-02-04 | 2002-06-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them |
US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
WO2000015213A1 (fr) * | 1998-09-11 | 2000-03-23 | Shionogi & Co., Ltd. | Agent de prevention ou de traitement de l'insuffisance cardiaque congestive |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6465508B1 (en) | 2000-02-25 | 2002-10-15 | Wyeth | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors |
US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
CA2464727A1 (en) | 2001-11-01 | 2003-05-08 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
KR100966705B1 (ko) * | 2001-12-20 | 2010-06-29 | 브리스톨-마이어스 스큅 컴퍼니 | β-아밀로이드 저해제로서의α-(Ν-술폰아미도)아세트아미드 유도체 |
US6864478B2 (en) * | 2002-04-22 | 2005-03-08 | Visx, Incorporation | Beam position monitoring for laser eye surgery |
WO2005021489A2 (en) | 2002-12-23 | 2005-03-10 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
WO2004060346A2 (en) | 2002-12-30 | 2004-07-22 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
US7537774B2 (en) * | 2005-12-23 | 2009-05-26 | Orion Therapeautics, Llc | Therapeutic formulation |
US20090069304A1 (en) * | 2006-03-03 | 2009-03-12 | Shionogi & Co., Ltd. | Mmp-13 selective inhibitor |
US20100099676A1 (en) * | 2006-11-02 | 2010-04-22 | Shionogi & Co., Ltd. | Sulfonylurea derivative capable of selectively inhibiting mmp-13 |
US8093276B2 (en) * | 2007-10-31 | 2012-01-10 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
CN102088855A (zh) * | 2008-05-08 | 2011-06-08 | 百时美施贵宝公司 | 2-芳基甘氨酰胺衍生物 |
US8044077B2 (en) * | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
US7977362B2 (en) * | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
US20110071199A1 (en) * | 2009-03-20 | 2011-03-24 | Bristol-Myers Squibb Company | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease |
TW201043269A (en) * | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0100158A3 (de) * | 1982-07-28 | 1985-03-27 | The Upjohn Company | (3-Pyridinyl)-heteroalkarylalkanole, ihre Alkansäuren und ihre Ester |
DE3330603A1 (de) * | 1983-08-25 | 1985-03-21 | Hoechst Ag, 6230 Frankfurt | Neue 2-amino-alkenylsulfonylharnstoffe |
GB8609630D0 (en) * | 1986-04-19 | 1986-05-21 | Pfizer Ltd | Anti-arrhythmia agents |
AU675689B2 (en) * | 1992-12-01 | 1997-02-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
CA2110524A1 (en) * | 1992-12-10 | 1994-06-11 | Gerald Burr Grindey | Antitumor compositions and methods of treatment |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB9406143D0 (en) * | 1993-03-29 | 1994-05-18 | Zeneca Ltd | Heterocyclic derivatives |
IT1266582B1 (it) * | 1993-07-30 | 1997-01-09 | Recordati Chem Pharm | Derivati (di)azacicloesanici e diazacicloeptanici |
CN1049651C (zh) * | 1994-01-20 | 2000-02-23 | 英国生物技术药物有限公司 | 金属蛋白酶抑制剂 |
US5514716A (en) * | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
US5817822A (en) * | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
US5919940A (en) * | 1995-01-20 | 1999-07-06 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
IL128545A0 (en) * | 1996-12-09 | 2000-01-31 | Warner Lambert Co | Method for treating and preventing heart failure and ventricular dilatation |
DE69727695T2 (de) * | 1996-12-17 | 2005-02-10 | Warner-Lambert Co. Llc | Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung |
-
1996
- 1996-10-18 PT PT96936718T patent/PT874836E/pt unknown
- 1996-10-18 AT AT96936718T patent/ATE225779T1/de not_active IP Right Cessation
- 1996-10-18 NZ NZ321293A patent/NZ321293A/en unknown
- 1996-10-18 HU HU9902083A patent/HUP9902083A3/hu unknown
- 1996-10-18 US US09/068,726 patent/US5977141A/en not_active Expired - Fee Related
- 1996-10-18 AU AU74641/96A patent/AU727569B2/en not_active Ceased
- 1996-10-18 EP EP96936718A patent/EP0874836B1/de not_active Expired - Lifetime
- 1996-10-18 SK SK641-98A patent/SK282833B6/sk unknown
- 1996-10-18 WO PCT/US1996/016761 patent/WO1997019068A1/en active IP Right Grant
- 1996-10-18 IL IL12390196A patent/IL123901A/xx not_active IP Right Cessation
- 1996-10-18 JP JP09519715A patent/JP2000514779A/ja not_active Abandoned
- 1996-10-18 PL PL96326700A patent/PL326700A1/xx unknown
- 1996-10-18 DE DE69624262T patent/DE69624262T2/de not_active Expired - Fee Related
- 1996-10-18 CZ CZ19981467A patent/CZ291659B6/cs not_active IP Right Cessation
- 1996-10-18 DK DK96936718T patent/DK0874836T3/da active
- 1996-10-18 BR BR9611487A patent/BR9611487A/pt not_active IP Right Cessation
- 1996-10-18 ES ES96936718T patent/ES2184893T3/es not_active Expired - Lifetime
- 1996-11-14 ZA ZA969584A patent/ZA969584B/xx unknown
-
1998
- 1998-05-13 BG BG102448A patent/BG63967B1/bg unknown
- 1998-05-15 NO NO19982223A patent/NO310231B1/no not_active IP Right Cessation
-
1999
- 1999-10-05 US US09/412,707 patent/US6153612A/en not_active Expired - Fee Related
-
2000
- 2000-06-22 US US09/599,306 patent/US6297247B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE225779T1 (de) | 2002-10-15 |
US6297247B1 (en) | 2001-10-02 |
EP0874836A1 (de) | 1998-11-04 |
US5977141A (en) | 1999-11-02 |
CZ291659B6 (cs) | 2003-04-16 |
NO310231B1 (no) | 2001-06-11 |
US6153612A (en) | 2000-11-28 |
HUP9902083A3 (en) | 2000-06-28 |
AU7464196A (en) | 1997-06-11 |
HUP9902083A2 (hu) | 1999-10-28 |
CZ146798A3 (cs) | 1998-08-12 |
IL123901A (en) | 2003-06-24 |
PL326700A1 (en) | 1998-10-26 |
NO982223D0 (no) | 1998-05-15 |
WO1997019068A1 (en) | 1997-05-29 |
SK282833B6 (sk) | 2002-12-03 |
BG102448A (en) | 1999-08-31 |
DE69624262D1 (de) | 2002-11-14 |
IL123901A0 (en) | 1998-10-30 |
SK64198A3 (en) | 1998-10-07 |
ES2184893T3 (es) | 2003-04-16 |
DE69624262T2 (de) | 2003-09-11 |
ZA969584B (en) | 1997-06-02 |
AU727569B2 (en) | 2000-12-14 |
JP2000514779A (ja) | 2000-11-07 |
DK0874836T3 (da) | 2003-02-10 |
NZ321293A (en) | 2001-04-27 |
BR9611487A (pt) | 1999-01-19 |
NO982223L (no) | 1998-05-15 |
PT874836E (pt) | 2003-02-28 |
EP0874836B1 (de) | 2002-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG63967B1 (bg) | Сулфонамидни инхибитори на матрични металопротеинази | |
US6117869A (en) | Compounds for and methods of inhibiting matrix metalloproteinases | |
EP0876343B1 (de) | Aromatische keto-säure und ihre derivate als inhibitoren der matrix metalloproteinase | |
MXPA01013324A (es) | Compuestos de acido hidroxamico utiles como inhibidores de metaloproteinasa de matriz. | |
HRP970474A2 (en) | Compounds for and a method of inhibiting matrix metalloproteinases | |
KR20000068414A (ko) | 매트릭스 메탈로프로테이나제 억제제 및 그의 치료적 용도 | |
CA2233560C (en) | Sulfonamide inhibitors of matrix metalloproteinases | |
US6624177B1 (en) | Matrix metalloproteinase inhibitors and their therapeutic uses | |
JP2001522843A (ja) | Mmpおよびtnf抑制作用を有するヒドロキサム酸およびカルボン酸誘導体 | |
MXPA98003315A (en) | Queto aromatic acids and their derivatives as inhibitors of metaloproteinases mat | |
MXPA98009871A (en) | Matrix metalloproteinase inhibitors and their therapeutic uses | |
MXPA98009929A (en) | Compounds for and a method of inhibiting matrix metalloproteinases |